1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Venetoclax-Azacitidine Versus Intensive Chemotherapy for Induction in Childhood Acute Myeloid Leukemia: A Comparative Analysis

AML - 993

Venetoclax-Azacitidine Versus Intensive Chemotherapy for Induction in Childhood Acute Myeloid Leukemia: A Comparative Analysis

Shyam Srinivasan

Poster Presenter: Shyam Srinivasan

$Thumbnail for Venetoclax-Based Salvage Therapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory AML: A Systematic Review and Meta-Analysis$

AML - 923

Venetoclax-Based Salvage Therapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory AML: A Systematic Review and Meta-Analysis

Bhaswanth Bollu

Poster Presenter: Bhaswanth Bollu

SOHO 2026 Annual Meeting

Posters by Title

Venetoclax-Azacitidine Versus Intensive Chemotherapy for Induction in Childhood Acute Myeloid Leukemia: A Comparative Analysis

Venetoclax-Based Salvage Therapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory AML: A Systematic Review and Meta-Analysis

Venetoclax-Based Therapy Is Associated With Improved Survival in Acute Myeloid Leukemia: A Large Real-World Study

Venetoclax in Combination With a Hypomethylating Agent for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Medically Unfit for Intensive Induction Therapy: A Real-World Community Experience

Venous Thromboembolism in Lymphoma: Risk Stratification and Evolving Anticoagulation Strategies

Venous Thromboembolism Is Associated With Greater 90-Day Morbidity and Inpatient Utilization Among Hospitalized Patients With Diffuse Large B-Cell Lymphoma: A Propensity-Matched TriNetX Analysis

Venous Thrombotic Outcomes in Pregnant Patients With Myeloproliferative Neoplasms: A Propensity Score-Matched Analysis

Vispa-cel, an Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

waveLINE-011: Zilovertamab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) vs Polatuzumab Vedotin Plus R-CHP as First-Line Therapy in Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma